Targeted therapy nel paziente anziano con carcinoma prostatico ormono-resistente

Translated title of the contribution: Targeted therapy in patients with metastatic hormone-refractory prostate cancer

Silvana Leo, C. Accettura, V. Lorusso

Research output: Contribution to journalArticle


Hormone-refractory prostate cancer is common and only the combination of docetaxel and prednisone has been shown to improve survival. Targeted therapies have revolutionized the treatment of cancer. Advances in our understanding of the molecular mechanism underlying prostate cancer progression has translated into a variety of treatment approaches. However, the treatment of elderly patients with these new biological therapies remains a challenge and few data are available concerning the toxicity of biological drugs in the elderly population.

Original languageItalian
Pages (from-to)58-66
Number of pages9
JournalGeriatric and Medical Intelligence
Issue number1
Publication statusPublished - 2010


ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this